Universal test and treat is not associated with sub-optimal antiretroviral therapy adherence in rural South Africa: the ANRS 12249 TasP trial

Collins Iwuji, Nuala McGrath, Alexandra Calmy, Francois Dabis, Deenan Pillay, Marie-Louise Newell, Kathy Baisley, Kholoud Porter, Collins Iwuji, Nuala McGrath, Alexandra Calmy, Francois Dabis, Deenan Pillay, Marie-Louise Newell, Kathy Baisley, Kholoud Porter

Abstract

Introduction: HIV treatment guidelines now recommend antiretroviral therapy (ART) initiation regardless of CD4 count to maximize benefit both for the individual and society. It is unknown whether the initiation of ART at higher CD4 counts would affect adherence levels. We investigated whether initiating ART at higher CD4 counts was associated with sub-optimal adherence (<95%) during the first 12 months of ART.

Methods: A prospective cohort study nested within a two-arm cluster-randomized trial of universal test and treat was implemented from March 2012 to June 2016 to measure the impact of ART on HIV incidence in rural KwaZulu-Natal. ART was initiated regardless of CD4 count in the intervention arm and according to national guidelines in the control arm. ART adherence was measured monthly using a visual analogue scale (VAS) and pill counts (PC). HIV viral load was measured at ART initiation, three and six months, and six-monthly thereafter. We pooled data from participants in both arms and used random-effects logistic regression models to examine the association between CD4 count at ART initiation and sub-optimal adherence, and assessed if adherence levels were associated with virological suppression.

Results: Among 900 individuals who initiated ART ≥12 months before study end, median (IQR) CD4 at ART initiation was 350 cells/mm3 (234, 503); median age was 34.6 years (IQR 27.4 to 46.4) and 71.7% were female. Adherence was sub-optimal in 14.7% of visits as measured by VAS and 20.7% by PC. In both the crude analyses and after adjusting for potential confounders, adherence was not significantly associated with CD4 count at ART initiation (adjusted OR for linear trend in sub-optimal adherence with every 100 cells/mm3 increase in CD4 count: 1.00, 95% CI 0.95 to 1.05, for VAS, and 1.03, 95% CI 0.99 to 1.07, for PC). Virological suppression at 12 months was 97%. Optimal adherence by both measures was significantly associated with virological suppression (p < 0.001 for VAS; p = 0.006 for PC).

Conclusions: We found no evidence that higher CD4 counts at ART initiation were associated with sub-optimal ART adherence in the first 12 months. Our findings should alleviate concerns about adherence in individuals initiating ART at higher CD4 counts, however long-term outcomes are needed. ClinicalTrials.gov NCT01509508.

Keywords: HIV; Africa; adherence; antiretroviral therapy; pill count; test and treat; virologic suppression; visual analogue scale.

© 2018 The Authors. Journal of the International AIDS Society published by John Wiley & sons Ltd on behalf of the International AIDS Society.

Figures

Figure 1
Figure 1
Flow chart of cohort.
Figure 2
Figure 2
Relationship between mean adherence levels over 12 months measured by visual analogue scale (upper panel) and pill count (lower panel) and virological suppression at 12 months.

References

    1. World Health Organisation . Guideline on when to start antiretroviral therapy and on pre‐exposure prophylaxix for HIV 2015 [cited 2016 Nov 9]. Available from: .
    1. Group TAS, Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–22. . PubMed PMID: 26193126.
    1. Group ISS, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807. . PubMed PMID: 26192873; PubMed Central PMCID: PMC4569751.
    1. National Department of Health SA . Implementation of the universal test and treat strategy for HIV positive patients and differentiated care for stable patients. 2016. [cited 2016 Dec 17].
    1. Charurat M, Oyegunle M, Benjamin R, Habib A, Eze E, Ele P, et al. Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: a longitudinal analysis for risk factors. PLoS ONE. 2010;5(5):e10584 . PubMed PMID: 20485670; PubMed Central PMCID: PMC2868044.
    1. Memiah P, Shumba C, Etienne‐Mesubi M, Agbor S, Hossain MB, Komba P, et al. The effect of depressive symptoms and CD4 count on adherence to highly active antiretroviral therapy in sub‐Saharan Africa. J Int Assoc Provid AIDS Care. 2014;13(4):346–52. PubMed PMID: 25513032.
    1. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354(3):251–60. . PubMed PMID: 16421366.
    1. UNAIDS . 90‐90‐90. An ambitious treatment target to help end the AIDS epidemic, 2014. [cited 2017 14 March]. Available from: .
    1. Izugbara CO, Wekesa E. Beliefs and practices about antiretroviral medication: a study of poor urban Kenyans living with HIV/AIDS. Sociol Health Illn. 2011;33(6):869–83. . PubMed PMID: 21371051.
    1. Iwuji C, Orne‐Gliemann J, Balestre E, Larmarange J, Thiebaut R, Tanser F, et al. The impact of universal test and treat on HIV incidence in a rural South African population: ANRS 12249 TasP trial, 2012–2016. International AIDS Conference; July 18‐22; Durban, South Africa 2016.
    1. Iwuji CC, Orne‐Gliemann J, Larmarange J, Okesola N, Tanser F, Thiebaut R, et al. Uptake of home‐based HIV testing, linkage to care, and community attitudes about ART in rural KwaZulu‐Natal, South Africa: descriptive results from the first phase of the ANRS 12249 TasP cluster‐randomised trial. PLoS Med. 2016;13(8):e1002107 . PubMed PMID: 27504637; PubMed Central PMCID: PMC4978506
    1. Iwuji CC, Orne‐Gliemann J, Tanser F, Boyer S, Lessells RJ, Lert F, et al. Evaluation of the impact of immediate versus WHO recommendations‐guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub‐district, KwaZulu‐Natal, South Africa: study protocol for a cluster randomised controlled trial. Trials. 2013;14:230 Epub 2013/07/25. . PubMed PMID: 23880306; PubMed Central PMCID: PMC3750830.
    1. World Health Organisation . Consolidated Guidelines on HIV Testing Services. 2015. [cited 2017, 8 June]. Available from: .
    1. Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol. 1999;28(5):964–74. PubMed PMID: 10597998.
    1. Kroenke K, Spitzer RL, Williams JB, Lowe B. An ultra‐brief screening scale for anxiety and depression: the PHQ‐4. Psychosomatics. 2009;50(6):613–21. . PubMed PMID: 19996233.
    1. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis. 2000;30(Suppl 2):S171–6. . PubMed PMID: 10860902.
    1. Langebeek N, Gisolf EH, Reiss P, Vervoort SC, Hafsteinsdottir TB, Richter C, et al. Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta‐analysis. BMC Med. 2014;12:142 . PubMed PMID: 25145556; PubMed Central PMCID: PMC4148019.
    1. Bock P, James A, Nikuze A, Peton N, Sabapathy K, Mills E, et al. Baseline CD4 count and adherence to antiretroviral therapy: a systematic review and meta‐analysis. J Acquir Immune Defic Syndr. 2016;73(5):514–21. . PubMed PMID: 27851712.
    1. World Health Organisation . Global report on early warning indicators oF HIV drug resistance. 2016. [cited 2017 Feb 15]. Available from: .
    1. Muya AN, Geldsetzer P, Hertzmark E, Ezeamama AE, Kawawa H, Hawkins C, et al. Predictors of nonadherence to antiretroviral therapy among HIV‐infected adults in Dar es Salaam, Tanzania. J Int Assoc Provid AIDS Care. 2015;14(2):163–71. . PubMed PMID: 24966305.
    1. Maqutu D, Zewotir T, North D, Naidoo K, Grobler A. Factors affecting first‐month adherence to antiretroviral therapy among HIV‐positive adults in South Africa. Afr J AIDS Res. 2010;9(2):117–24. Epub 2011/07/23. . PubMed PMID: 21779200; PubMed Central PMCID: PMC3137932.
    1. Camlin CS, Snow RC, Hosegood V. gendered patterns of migration in rural South Africa. Popul Space Place. 2014;20(6):528–51. . PubMed PMID: 25332690; PubMed Central PMCID: PMCPMC4201383
    1. Lima VD, Reuter A, Harrigan PR, Lourenco L, Chau W, Hull M, et al. Initiation of antiretroviral therapy at high CD4 + cell counts is associated with positive treatment outcomes. AIDS. 2015;29(14):1871–82. . PubMed PMID: 26165354; PubMed Central PMCID: PMC4573912
    1. Chi BH, Cantrell RA, Zulu I, Mulenga LB, Levy JW, Tambatamba BC, et al. Adherence to first‐line antiretroviral therapy affects non‐virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia. Int J Epidemiol. 2009;38(3):746–56. Epub 2009/02/19. . PubMed PMID: 19223334; PubMed Central PMCID: PMC2689395.
    1. O'Connor JL, Gardner EM, Mannheimer SB, Lifson AR, Esser S, Telzak EE, et al. Factors associated with adherence amongst 5295 people receiving antiretroviral therapy as part of an international trial. J Infect Dis. 2013;208(1):40–9. . PubMed PMID: 23204161; PubMed Central PMCID: PMC3666133.
    1. Haubrich RH, Little SJ, Currier JS, Forthal DN, Kemper CA, Beall GN, et al. The value of patient‐reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS. 1999;13(9):1099–107. PubMed PMID: 10397541.
    1. Oyugi JH, Byakika‐Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, Kityo C, et al. Treatment interruptions predict resistance in HIV‐positive individuals purchasing fixed‐dose combination antiretroviral therapy in Kampala, Uganda. AIDS. 2007;21(8):965–71. . PubMed PMID: 17457090.
    1. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30. Epub 2000/07/06 PubMed PMID: 10877736.
    1. Hong SY, Fanelli TJ, Jonas A, Gweshe J, Tjituka F, Sheehan HM, et al. Household food insecurity associated with antiretroviral therapy adherence among HIV‐infected patients in Windhoek, Namibia. J Acquir Immune Defic Syndr. 2014;67(4):e115–22. . PubMed PMID: 25356779; PubMed Central PMCID: PMC4215168.
    1. Weiser SD, Fernandes KA, Brandson EK, Lima VD, Anema A, Bangsberg DR, et al. The association between food insecurity and mortality among HIV‐infected individuals on HAART. J Acquir Immune Defic Syndr. 2009;52(3):342–9.
    1. Weiser SD, Frongillo EA, Ragland K, Hogg RS, Riley ED, Bangsberg DR. Food insecurity is associated with incomplete HIV RNA suppression among homeless and marginally housed HIV‐infected individuals in San Francisco. J Gen Intern Med. 2008;24:14–20.
    1. Sanjobo N, Frich JC, Fretheim A. Barriers and facilitators to patients’ adherence to antiretroviral treatment in Zambia: a qualitative study. SAHARA J. 2008;5(3):136–43. PubMed PMID: 18979047.
    1. Unge C, Johansson A, Zachariah R, Some D, Van Engelgem I, Ekstrom AM. Reasons for unsatisfactory acceptance of antiretroviral treatment in the urban Kibera slum, Kenya. AIDS Care. 2008;20(2):146–9. . PubMed PMID: 18293122.
    1. WHO . Adherence to long term therapies. Evidence for action. 2003 [cited 2013 Sept 22]. Available from: .
    1. Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S79–87. . PubMed PMID: 17133207; PubMed Central PMCID: PMC2866146.
    1. Protopopescu C, Carrieri MP, Raffi F, Picard O, Hardel L, Piroth L, et al. Brief report: prolonged viral suppression over a 12‐year follow‐up of HIV‐infected patients: the persistent impact of adherence at 4 months after initiation of combined antiretroviral therapy in the ANRS CO8 APROCO‐COPILOTE cohort. J Acquir Immune Defic Syndr. 2017;74(3):293–7. . PubMed PMID: 27861235.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する